Læknablaðið - 15.03.2003, Síða 35

FRÆÐIGREINAR / FJÖLÓMETTAÐAR FITUSÝRUR OG LÆKNINGAR
121. Gibson SW, Valente JF, Alexander JW, Custer DA, Babcock GF, Ogle CK.
The effect of nutritional immunomodulation on cardiac allograft survival in
rats receiving mycophenolate mofetil, cyclosporine A, and donor-specific
transfusion. J Heart Lung Transplant 1999; 18:185-9.
122. Katznelson S, Wilkinson AH. HMGCoA reductase inhibitors and omega-3
fatty acids as adjunctive agents in maintenance immunosuppression after
solid organ transplantation. Clin Transplant 1995; 9: 197-200.
123. Buck AC, Lote CJ, Sampson WF. The influence of renal prostaglandins on
urinary calcium excretion in idiopathic urolithiasis. J Urol 1983; 139:421-6.
124. Baggio B, Budakovic A, Nassuato MA, Vezzoli G, Manzato E, Luisetto G, et al.
Plasma phospholipid arachidonic acid content and calcium metabolism in
idiopathic calcium nephrolithiasis. Kidney Int 2000; 58:1278-84.
125. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of
arteriovenous grafts in hemodialysis patients. Am J Kidney Dis (computer
file) 2000; 36:68-74.
126. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis
of hemodialysis graft thrombosis with fish oil: double-blind, randomized,
prospective trial. J Am Soc Nephrol 2002; 13:184-90.
127. Mischoulon D, Fava M. Docosahexanoic acid and omega-3 fatty acids in
depression. Psych Clin N Am 2000; 23:785-94.
128. Maidment ID. Are fish oils an effective therapy in mental illness-an analysis of
the data. Acta Psych Scand 2000; 102:3-11.
129. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in post-
mortem brains from schizophrenic patients. Schizophrenia Res 2000; 42:7-17.
130. Salem NJ, Wegher B, Mena P, Uauy R. Arachidonic and docosahexaenoic
acids are biosynthesized from their 18-carbon precursors in human infants.
Proc Nat Acad Sc USA 1996; 93: 49-54.
131. Sanders TA, Reddy S. The influence of a vegetarian diet on the fatty acid
composition of human milk and the essential fatty acid status of the infant. J
Ped 1992; 120: Suppl: S71-S77.
132. Emmett PM, Rogers IS. Properties of human milk and their relationship with
maternal nutrition. Early Human Develop 1997; 49 Suppl: S7-28.
133. Ólafur Reykdal. íslenskur gagnagrunnur um efnainnihald matvæla (ÍSGEM).
Reykjavík: Rannsóknarstofnun landbúnaöarins. 1998.
134. Farquharson J, Cockbum F, Patrick WA, Jamieson EC, Logan RW. Infant
cerebral cortex phospholipid fatty-acid composition and diet. Lancet 1992;
340:810-3.
135. SanGiovanni JP, Parra-Cabrera S, Colditz GA, Berkey CS, Dwyer JT. Meta-
analysis of dietary essential fatty acids and long-chain polyunsaturated fatty
acids as they relate to visual resolution acuity in healthy preterm infants.
Pediatrics 2000; 105:1292-8.
136. SanGiovanni JP, Berkey CS, Dwyer JT, Colditz GA. Dietary essential fatty acids,
long-chain polyunsaturated fatty acids, and visual resolution acuity in healthy
fullterm infants: a systematic review. Early Human Develop 2000; 57:165-88.
137. Morrow-Tlucak M, Haude RH, Emhart CB. Breastfeeding and cognitive
development in the fírst 2 years of life. Soc Sci Med 1988; 26:635-9.
138. O'Connor DL, Hall R, Adamkin D, Auestad N, Castillo M, Connor WE, et
al. Growth and development in preterm infants fed long-chain polyunsatura-
ted fatty acids: a prospective, randomized controlled trial. Pediatrics 2001;
108: 359-71.
139. Auestad N, Halter R, Hall RT, Blatter M, Bogle ML, Burks W, et al. Growth
and development in term infants fed long-chain polyunsaturated fatty acids: a
double-masked, randomized, parallel, prospective, multivariate study.
Pediatrics 2001; 108:372-81.
140. Lucas A, Stafford M, Morley R, Abbott R, Stephenson T, MacFadyen U, et
al. Efficacy and safety of long-chain polyunsaturated fatty acid supplementa-
tion of infant-formula milk: a randomised trial. Lancet 1999; 354:1948-54.
141. Makrides M, Neumann MA, Simmer K, Gibson RA. A critical appraisal of the
role of dietary long-chain polyunsaturated fatty acids on neural indices of term
infants: a randomized, controlled trial. Pediatrics 2000; 105:32-8.
142. Birch EE, Garfield S, Hoffman DR. Uauy R, Birch DG. A randomized
controlled trial of early dietary supply of long-chain polyunsaturated fatty
acids and mental development in term infants. Develop Med Child Neurol
2000; 42:174-81.
143. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et
al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind,
placebo-controlled trial. Arch Gen Psych 1999; 56:407-12.
144. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane
abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psych
2000; 47:8-21.
145. Horrobin DF. The membrane phosphoiipid hypothesis as a biochemical basis
for the neurodevelopmental concept of schizophrenia. Schizophrenia Res
1998; 30:193-208.
146. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind
placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of
schizophrenia. Schizophrenia Res 2001; 49:243-51.
147. Richardson AJ, Easton T, Puri BK. Red cell and plasma fatty acid changes
accompanying symptom remission in a patient with schizophrenia treated
with eicosapentaenoic acid. Eur Neuropsychopharmacol 2000; 10:189-93.
148. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid
levels in red blood cell membranes of depressive patients. Biol Psych 1998; 43:
315-9.
149. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viina-
maki H. Fish consumption, depression, and suicidality in a general popula-
tion. Arch Gen Psych 2001; 58: 512-3.
150. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid
levels in the diet and in red blood cell membranes of depressed patients. J Aff
Disord 1998; 48:149-55.
151. Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. Lipids
1996; 31 Suppl: S163-S165.
152. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in
schizophrenia. II. Fatty acid composition. Schizophrenia Res 1994; 13:217-26.
153. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the
brains of schizophrenics and normal controls. Biol Psych 1991; 30:795-805.
154. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Morrison-Stewart S,
et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-
MR spectroscopy study. Schizophrenia Res 1994; 13:209-15.
155. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta
MG, et al. Alterations in brain high-energy phosphate and membrane phospho-
lipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the
dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance
spectroscopy. Arch Gen Psych 1991; 48:563-8.
156. Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T.
Changes in levels of phosphorus metabolites in temporal lobes of drug-naive
schizophrenic patients. Am J Psych 1999; 156:1205-8.
157. Horrobin DF, Bennett CN. New gene targets related to schizophrenia and
other psychiatric disorders: enzymes, binding proteins and transport proteins
involved in phospholipid and fatty acid metabolism. Prostagland Leukotri Ess
Fatty Acids 1999; 60:141-67.
158. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid
breakdown in schizophrenia. Evidence for the involvement of a calcium-
independent phospholipase A2. Arch Gen Psych 1997; 54:487-94.
159. Horrobin DF. Lipids and schizophrenia. Br J Psych 1999; 175:88.
160. Marteinsdóttir I, Horrobin DF, Stenfors C, Theodorsson E, Mathe AA.
Changes in dietary fatty acids alter phospholipid fatty acid composition in
selected regions of rat brain. Progr Neuro-Psychopharmacol Biol Psych 1998;
22:1007-21.
161. Bucher H, Rampini S, James RW, Pometta D, Funke H, Wiebusch H, et al.
Marked changes of lipid levels during puberty in a patient with lipoprotein
lipase deficiency. Eur J Ped 1997; 156:121-5.
162. Su KSW. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant
schizophrenic patient. Eur Neuropsychopharmacol 2001; 11: 295-9.
163. DeCaterina R, Giannessi D, Mazzone A, Bernini W, Lazzerini G, Maffei S, et
al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsatu-
rated fatty acids before coronary artery bypass graft surgery. Circulation 1990;
82:428-38.
164. Salonen JT, Seppanen K, Nyyssonen K, Korpela H, Kauhanen J, Kantola M,
et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocar-
dial infarction and coronary, cardiovascular, and any death in eastern Finnish
men. Circulation 1995; 91: 645-55.
165. Kulas E, Ackman RG. Different tocopherols and the relationship between
two methods for determination of primary oxidation products in fish oil. J
Agricult Food Chem 2001; 49:1724-9.
166. Schmidt EB, Skou HA, Christensen JH, Dyerberg J. N-3 fatty acids from fish
and coronary artery disease: implications for public health. Publ Health Nutr
2000; 3:91-8.
167. Nestel P. Effects of fish oils and fish on cardiovascular disease. Curr Athero-
sclerosis Rep 2001; 3:68-73.
168. Stone NJ. The Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto
Miocardio (GlSSI)-Prevenzione Trial on fish oil and vitamin E supplementa-
tion in myocardial infarction survivors. Curr Cardiol Rep 2000; 2:445-1.
169. Ackman RG. The absorption of fish oils and concentrates. Lipids 1992; 27:
858-62.
170. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA).
Pharmacol Res 1999; 40: 211-25.
171. Crawford MA, Bloom M, Broadhurst CL, Schmidt WF, Cunnane SC, Galli C,
et al. Evidence for the unique function of docosahexaenoic acid during the
evolution of the modern hominid brain. Lipids 1999; 34 Suppl: S39-S47.
172. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential
effects of eicosapentaenoic acid and docosahexaenoic acid on vascular
reactivity of the forearm microcirculation in hyperlipidemic, overweight men.
Circulation 2000; 102:1264-9.
Læknablaðið 2003/89 211